Giuffrè et al previously encountered a HER2 overexpression rate of 21.10% in a smaller cohort of gastric adenocarcinomas that were obtained from a single pathological unit (16), which is consistent with the results that have been reported elsewhere in the literature (11,19,21,25–28), in which the mean HER2 positivity rate, using FISH or chromogenic in situ hybridization, was 19.2% (range, 7.1–42.6%) (25). This evidence concerns the gene ERBB2 and gastric adenocarcinoma.